Skip to main content

Mesenchymal Stem Cells for Multiple Sclerosis: Does Neural Differentiation Really Matter?

Buy Article:

$68.00 + tax (Refund Policy)

The lack of therapies fostering remyelination and regeneration of the neural network deranged by the autoimmune attack occurring in multiple sclerosis (MS) is raising great expectations about stem cells therapies for tissue repair. Mesenchymal stem cells (MSCs) have been proposed as a possible treatment for MS due to the reported capacity of transdifferentiation into neural cells and their ability at modulating immune responses. However, recent studies have demonstrated that many other functional properties are likely to play a role in the therapeutic plasticity of MSCs, including antiapoptotic, trophic and anti-oxidant effects. These features are mostly based on the paracrine release of soluble molecules, often dictated by local environmental cues. Based on the modest evidence of long-term engraftment and the striking clinical effects that are observed immediately after MSCs administration in the experimental model of MS, we do not favor a major role for transdifferentiation as an important mechanism involved in the therapeutic effect of MSCs.

Keywords: B cells; Mesenchymal stem cells; T cells; adaptive immunity; autoimmunity; bone marrow (BM); brain-derived neurotrophic factor; central nervous system; chemokine receptors; cytokine; dendritic; embryonic stem cells; experimental autoimmune encephalomyelitis; graft versus host; hematopoietic stem cells (HSC); immunogenicity; inflammation; mesenchymal multipotent progenitor cells; multiple sclerosis; myelin oligodendrocyte glycoprotein; natural killer cells; neural cells; neural precursor; neuro-genesis; oligodendrogenesis; oxidative stress; paracrine mechanisms; proteolipid protein (PLP); remyelination; stroke

Document Type: Research Article

Publication date: March 1, 2011

More about this publication?
  • Current Stem Cell Research & Therapy publishes frontier reviews on all aspects of basic research on stem cells and their uses in clinical therapy. The journal's aim is to publish the highest quality review articles in the field. The journal is essential reading for all researchers and clinicians involved in stem cells.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content